Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid β-peptides.
暂无分享,去创建一个
M. Staufenbiel | J. Rondeau | S. Desrayaud | H. Möbitz | L. Jacobson | U. Neumann | H. Rueeger | R. Lueoend | R. Machauer | S. Veenstra | Henrik Möbitz
[1] Jean-Michel Rondeau,et al. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides. , 2012, Journal of medicinal chemistry.
[2] A. Maguire,et al. Copper-catalyzed asymmetric oxidation of sulfides. , 2012, The Journal of organic chemistry.
[3] B. de Strooper,et al. The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing , 2011, Journal of neurochemistry.
[4] A. Vulpetti,et al. Fluorine–Protein Interactions and 19F NMR Isotropic Chemical Shifts: An Empirical Correlation with Implications for Drug Design , 2011, ChemMedChem.
[5] M. Citron,et al. Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.
[6] C. Dingwall,et al. Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics. , 2009, Bioorganic & medicinal chemistry letters.
[7] A. Simon,et al. In Vivo β-Secretase 1 Inhibition Leads to Brain Aβ Lowering and Increased α-Secretase Processing of Amyloid Precursor Protein without Effect on Neuregulin-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.
[8] Yu Yuan,et al. Gold(III) catalyzed oxidation of sulfides to sulfoxides with hydrogen peroxide , 2007 .
[9] Kazuhiro Matsumoto,et al. Asymmetric oxidation catalysis by a chiral Al(salalen) complex: highly enantioselective oxidation of sulfides with aqueous hydrogen peroxide. , 2007, Angewandte Chemie.
[10] P. Wong,et al. Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.
[11] R. de Kanter,et al. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.
[12] P. Saftig,et al. Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.
[13] Rudi D'Hooge,et al. Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice* , 2005, Journal of Biological Chemistry.
[14] C. Bolm,et al. Investigations on the iron-catalyzed asymmetric sulfide oxidation. , 2005, Chemistry.
[15] M. Boffito,et al. The pharmacokinetics of HIV protease inhibitor combinations , 2005, Current opinion in infectious diseases.
[16] R. Greenblatt,et al. Sex differences in pharmacokinetics and pharmacodynamics. , 2004, Annual review of pharmacology and toxicology.
[17] Stephen A. Wring,et al. Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.
[18] I. Kola,et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.
[19] D. Back,et al. Principles and practice of HIV‐protease inhibitor pharmacoenhancement , 2001, HIV medicine.
[20] H. Cai,et al. BACE1 is the major β-secretase for generation of Aβ peptides by neurons , 2001, Nature Neuroscience.
[21] W. Richards,et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.
[22] J. Tang,et al. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[23] R. Barbour,et al. Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.
[24] Alfredo G. Tomasselli,et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.
[25] David G. Tew,et al. Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.
[26] J. Treanor,et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.
[27] R. Neve,et al. Age-Dependent Neuronal and Synaptic Degeneration in Mice Transgenic for the C Terminus of the Amyloid Precursor Protein , 1996, The Journal of Neuroscience.
[28] J. Hardy,et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.
[29] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[30] Carl R. Johnson,et al. The Stereochemistry of Oxidation at Sulfur. Oxidation of 4-Substituted Thianes to Sulfoxides1 , 1965 .
[31] Carl R. Johnson,et al. Equilibration of 4-Substituted Thiane 1-Oxides , 1964 .
[32] H. Kagan,et al. Asymmetric oxidation of sulfides mediated by chiral titanium complexes : mechanistic and synthetic aspects , 1987 .